Clinical Trials on Primary Sclerosing Cholangitis

Total 63281 results

CymaBay Therapeutics, Inc.

Recruiting

IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) (IDEAL)

Primary Biliary Cholangitis

United States
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis (AFFIRM)

Primary Biliary Cholangitis

United States, Korea, Republic of, Turkey
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Zydus Therapeutics Inc.

Recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Primary Biliary Cholangitis

United States
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Cascade Pharmaceuticals, Inc

Completed

Study of [14C]CS0159 in China Healthy Subjects

Primary Biliary Cholangitis

China
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Cascade Pharmaceuticals, Inc

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

Primary Biliary Cholangitis

China
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Biocad

Terminated

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Liver Cirrhosis, Biliary

Russian Federation
SAMEY
Axonal-Biostatem

Unknown

A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life (OCARELIFE)

Primary Biliary Cholangitis

France
Hospital Mutua de Terrassa

Recruiting

Detection Program for Patients With Primary Biliary Cholangitis Lost in the System (RESCAT)

Primary Biliary Cholangitis

Spain
Peking Union Medical College Hospital

Recruiting

Clinical Research of UCDA Reducing Medication Regimen in Stable PBC (UCDA PBC)

Primary Biliary Cholangitis

China
University of Alberta
Merck Sharp & Dohme LLC

Completed

Combination Antiretroviral Therapy (cART) for PBC

Primary Biliary Cholangitis

Canada
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates; Triangle Biostatistics

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Spain, Canada, Australia, United Kingdom, Germany, Netherlands, Belgium, Austria, France
Eli Lilly and Company

Terminated

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Primary Biliary Cholangitis

United States, Puerto Rico
West China Hospital

Unknown

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Nantes University Hospital

Unknown

Is Short Antibiotherapy Duration After Drainage Suitable for Patients Admitted in Intensive Care Medicine With a Severe Acute Cholangitis? (CASCAD)

Acute Cholangitis

France
Teikyo University

Completed

Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis

Primary Biliary Cirrhosis

Japan
Yilihamu·Abilitifu

Completed

The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
University of Alberta

Completed

Online Wellness Intervention for Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis

Canada
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
University of Birmingham
University Hospital Birmingham NHS Foundation Trust; Intercept Pharmaceuticals

Terminated

EXerCise Intervention in cholesTatic LivEr Disease: The EXCITED Study (EXCITED)

Primary Biliary Cholangitis

United Kingdom
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

Primary Biliary Cholangitis | Liver Stiffness

United States, Spain, France, Australia, Israel, Canada, Switzerland, Italy, New Zealand, Germany, Poland, Greece, United Kingdom, Belgium, Austria, Czechia, Hungary, Sweden
Innovative Digestive Health Education and Research...
NinePoint Medical

Unknown

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study (VLE-IOV)

Cholangiocarcinoma | Bile Duct Cancer | Primary Sclerosing Cholangitis | Bile Duct Diseases | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Bile Duct Neoplasms | Biliary Stricture | Bile Duct Obstruction | Bile Duct Obstruction, Extrahepatic | Pancreatic Duct Stricture | Bile Duct Lesions | Bile Duct Neoplasms... and other conditions

United States
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
University of Milano Bicocca
Intercept Pharmaceuticals; Laboratoires Mayoly Spindler

Recruiting

National Database on Primary Biliary Cholangitis (PBC322)

Primary Biliary Cholangitis

Italy
Fondazione Epatocentro Ticino

Recruiting

Swiss Primary Biliary Cholangitis Cohort Study

Liver Cirrhosis, Biliary

Switzerland
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Study Group

Withdrawn

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES-PBC)

Primary Biliary Cholangitis

United States
Yale University
American Liver Foundation

Suspended

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
West China Hospital

Completed

The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital

Primary Biliary Cholangitis

China
EA Pharma Co., Ltd.

Terminated

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Primary Biliary Cholangitis

Japan
West China Hospital

Unknown

Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1

Hepatitis | Autoimmune | Primary Biliary Cholangitis

China
Xiaoli Fan

Completed

Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital

Liver Diseases | Liver Cirrhosis | Cholangitis | Bile Duct Diseases | Cholestasis | Liver Cirrhosis, Biliary

China
CymaBay Therapeutics, Inc.

Recruiting

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Hepatic Impairment | Compensated Cirrhosis | Primary Biliary Cholangitis

Korea, Republic of, United States, Spain, United Kingdom
University of Leipzig
Hannover Medical School; RWTH Aachen University; Academisch Medisch Centrum -... and other collaborators

Recruiting

Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis (PBC-Cohort)

Primary Biliary Cholangitis | PBC

Germany
Asian Institute of Gastroenterology, India

Recruiting

Urgent (<24 Hours) Versus Early (24 to 48 Hours) ERCP for Patients With Mild and Moderate Acute Cholangitis

Acute Cholangitis

India
Seoul National University Hospital

Active, not recruiting

The Necessity of Bile Cultures in Patients With Acute Cholangitis

Acute Cholangitis

Korea, Republic of
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (VANTAGE)

Primary Biliary Cholangitis | PBC

United States, United Kingdom, Israel, Germany, Italy, France
GlaxoSmithKline

Recruiting

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Pruritus

United States, France, Italy, Japan, Spain, United Kingdom, Bulgaria, Germany, Greece, China, Argentina, Belgium, Brazil, Canada, Czechia, Israel, Mexico, Poland, Russian Federation, Switzerland
West China Hospital

Recruiting

Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II

Hepatitis, Autoimmune | Primary Biliary Cholangitis

China

Clinical Trials on Primary Sclerosing Cholangitis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations